Industry Symposium: Key issues around bone health
Supported by Amgen
Amgen oncology

Saturday, October 13, 2018
11:30 – 13:00

Chairperson Nick Murray, Australia                                                                                                                                                                     Hall B
11:30 – 12:00
11:30
11:40
11:50		 DEBATE: That a bone targeted agent should be routine for post-menopausal HR+ve patients
Yes: Arlene Chan, Australia
No: Nicholas Wilcken, Australia
Discussion
12:00 – 12:20 Bone agents for stage 4 disease: How long, for how often and at what cost?
Richard de Boer, Australia
12:20 – 12:40 The mythology of Vitamin D in disease
Ego Seeman, Australia
12:40 – 13:00 Discussion